Potential Appreciation, Aastrom Bioscience (ASTM)
September 23rd, 2010
No comments
The failure of Sanofi-Aventis and Vical’s, Temusi in a phase III program for CLI … opens the door … for ASTM and their phase III ready autologous cell therapy treatment. Read more…
